サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1561658

血友病市場レポート：タイプ別、治療別、療法別、地域別、2024年～2032年

Hemophilia Market Report by Type (Hemophilia A, Hemophilia B, Hemophilia C, and Others), Treatment (On-Demand, Prophylaxis), Therapy (Replacement Therapy, ITI Therapy, Gene Therapy), and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 135 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.25円
血友病市場レポート：タイプ別、治療別、療法別、地域別、2024年～2032年
出版日: 2024年09月10日
発行: IMARC
ページ情報: 英文 135 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の血友病市場の市場規模は2023年に130億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに312億米ドルに達し、2024年から2032年の間に9.9%の成長率（CAGR）を示すと予測しています。

血友病は、血液凝固プロセスに影響を及ぼす遺伝性疾患であり、血液が異常に凝固します。その結果、怪我や手術、歯科処置の後に、自然出血や過剰出血、あざができやすくなったり、にじみ出たりします。遺伝性の凝固因子欠乏症で、十分な血液凝固蛋白が欠乏するために血液凝固が遅くなります。治療には薬物療法、補充療法、凝固因子や血漿の注射が用いられます。その治療は、欠乏しているタンパク質を補い、合併症を予防することに重点を置いています。

血友病市場傾向：

血友病患者数の増加、および世界の遺伝子異常の増加は、市場にプラスの影響を与える主要因のひとつです。加えて、血友病の診断率の上昇や、血友病を治癒するための予防的治療の人気の高まりは、主要な市場プレイヤーに有利な成長機会を提供しています。これとは別に、各国の行政機関は、早期診断の利点についての認識を広め、新生児の早期スクリーニングを促進するための適切な手順に従うよう、数多くのキャンペーンを実施しており、これは市場に明るい見通しを生み出しています。さらに、治療の選択肢が限られているため、研究開発（R&D）活動への資金援助も増えています。さらに、業界をリードする企業各社は、血友病治療の有効性と精度を高めるために、技術的に進歩した診断ツールや治療法の導入に注力しており、これが良好な市場見通しをもたらしています。さらに、世界各地で血友病専門治療センター（HTC）の設立を拡大するための大規模な投資が市場を牽引すると予想されています。

本レポートで扱う主な質問

  • 2023年の世界の血友病市場の市場規模は？
  • 2024年から2032年にかけての世界の血友病市場の予想成長率は？
  • 世界の血友病市場を牽引する主要因は何か？
  • 世界の血友病市場に対するCOVID-19の影響は？
  • 世界の血友病市場のタイプ別内訳は？
  • 世界の血友病市場の治療別の内訳は？
  • 療法に基づく世界の血友病市場の内訳は？
  • 血友病市場の世界における主要地域は？
  • 世界の血友病市場における主要プレイヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の血友病市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • 血友病A
    • 市場動向
    • 市場予測
  • 血友病B
    • 市場動向
    • 市場予測
  • 血友病C
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：治療別

  • オンデマンド
    • 市場動向
    • 市場予測
  • 予防
    • 市場動向
    • 市場予測

第8章 市場内訳：療法別

  • 補充療法
    • 市場動向
    • 市場予測
  • ITI療法
    • 市場動向
    • 市場予測
  • 遺伝子治療
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Baxter International Inc.
    • Bayer AG
    • BioMarin Pharmaceutical Inc.
    • CSL Behring（CSL Limited）
    • F. Hoffmann-La Roche AG
    • Grifols S.A.
    • Kedrion S.p.A.
    • Novo Nordisk A/S
    • Octapharma AG
    • Pfizer Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
図表

List of Figures

  • Figure 1: Global: Hemophilia Market: Major Drivers and Challenges
  • Figure 2: Global: Hemophilia Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hemophilia Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Hemophilia Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Hemophilia Market: Breakup by Treatment (in %), 2023
  • Figure 6: Global: Hemophilia Market: Breakup by Therapy (in %), 2023
  • Figure 7: Global: Hemophilia Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Hemophilia (Hemophilia A) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Hemophilia (Hemophilia A) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Hemophilia (Hemophilia B) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Hemophilia (Hemophilia B) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Hemophilia (Hemophilia C) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Hemophilia (Hemophilia C) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Hemophilia (Other Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Hemophilia (Other Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Hemophilia (On-Demand) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Hemophilia (On-Demand) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Hemophilia (Prophylaxis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Hemophilia (Prophylaxis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Hemophilia (Replacement Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Hemophilia (Replacement Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Hemophilia (ITI Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Hemophilia (ITI Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Hemophilia (Gene Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Hemophilia (Gene Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Hemophilia Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Hemophilia Industry: SWOT Analysis
  • Figure 76: Global: Hemophilia Industry: Value Chain Analysis
  • Figure 77: Global: Hemophilia Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hemophilia Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Hemophilia Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Hemophilia Market Forecast: Breakup by Treatment (in Million US$), 2024-2032
  • Table 4: Global: Hemophilia Market Forecast: Breakup by Therapy (in Million US$), 2024-2032
  • Table 5: Global: Hemophilia Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Hemophilia Market: Competitive Structure
  • Table 7: Global: Hemophilia Market: Key Players
目次
Product Code: SR112024A4508

The global hemophilia market size reached US$ 13.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 31.2 Billion by 2032, exhibiting a growth rate (CAGR) of 9.9% during 2024-2032.

Hemophilia is an inherited medical disorder that affects the blood clotting process, wherein the blood clots abnormally. It results in spontaneous and excessive bleeding, easy bruising, and oozing after an injury, surgery, and dental procedures. It is caused by a hereditary lack of a coagulation factor that slows down blood clotting due to the deficiency of adequate blood-clotting proteins. It can be treated using medications, replacement therapy and injections of a clotting factor or plasma. Its treatment focuses on replacing missing proteins and preventing complications.

Hemophilia Market Trends:

The increasing number of hemophilic patients and rising occurrences of genetic abnormalities among individuals across the globe represents one of the key factors positively influencing the market. In addition, the rising diagnosis rate of the illness and the growing popularity of prophylactic treatment to cure hemophilia are offering lucrative growth opportunities to leading market players. Apart from this, governing agencies of various countries are organizing numerous campaigns to spread awareness about the benefits of early diagnosis and following appropriate procedures to facilitate the early screening of neonates, which is creating a positive outlook for the market. Additionally, they are increasingly funding research and development (R&D) activities due to the limited availability of treatment options. Furthermore, leading industry players are focusing on introducing technologically advanced diagnostic tools and therapies to enhance the efficacy and accuracy of hemophilia treatment, which is offering a favorable market outlook. Moreover, extensive investments in expanding the establishment of specialized hemophilia treatment centers (HTCs) across the globe are anticipated to drive the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hemophilia market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, treatment, and therapy.

Breakup by Type:

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Others

Hemophilia A represents the largest market segment due to the rising prevalence of hemophilia A among individuals across the globe and the increasing requirement for patient care.

Breakup by Treatment:

  • On-Demand
  • Prophylaxis

On-demand treatment currently holds the largest market share as it is highly beneficial for patients with mild or moderate hemophilia who bleed less often.

Breakup by Therapy:

  • Replacement Therapy
  • ITI Therapy
  • Gene Therapy

Replacement therapy is a standard therapy used to treat hemophilia as it helps replace the missing clotting factor among patients. It involves offering the missing clotting factor to patients from an external source.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance in the market due to the increasing government spending on healthcare and research and development (R&D) activities, along with the presence of various leading players in the country.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Bayer AG, BioMarin Pharmaceutical Inc., CSL Behring (CSL Limited), F. Hoffmann-La Roche AG, Grifols S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Key Questions Answered in This Report

  • 1. What was the size of the global hemophilia market in 2023?
  • 2. What is the expected growth rate of the global hemophilia market during 2024-2032?
  • 3. What are the key factors driving the global hemophilia market?
  • 4. What has been the impact of COVID-19 on the global hemophilia market?
  • 5. What is the breakup of the global hemophilia market based on the type?
  • 6. What is the breakup of the global hemophilia market based on the treatment?
  • 7. What is the breakup of the global hemophilia market based on the therapy?
  • 8. What are the key regions in the global hemophilia market?
  • 9. Who are the key players/companies in the global hemophilia market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hemophilia Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Hemophilia A
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Hemophilia B
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Hemophilia C
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Treatment

  • 7.1 On-Demand
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Prophylaxis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Therapy

  • 8.1 Replacement Therapy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 ITI Therapy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Gene Therapy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Baxter International Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 BioMarin Pharmaceutical Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 CSL Behring (CSL Limited)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 F. Hoffmann-La Roche AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Grifols S.A.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Kedrion S.p.A.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Novo Nordisk A/S
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Octapharma AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 SWOT Analysis
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Sanofi S.A.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Takeda Pharmaceutical Company Limited
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis